PRESS RELEASE published on 11/18/2025 at 12:52, 6 months 5 days ago Rapport Financier Semestriel 2025
BRIEF published on 11/14/2025 at 23:10, 6 months 9 days ago MaaT Pharma: successful fundraising of 9.1 million euros Investors Biotechnology Fundraising Microbiome Medical Innovation
BRIEF published on 11/14/2025 at 23:10, 6 months 9 days ago MaaT Pharma : levée de fonds réussie de 9,1 millions d'euros Biotechnologie Innovation Médicale Investisseurs Microbiome Levée De Fonds
PRESS RELEASE published on 11/14/2025 at 23:05, 6 months 9 days ago Inside Information / Operations of the issuer (acquisitions, sales...) MaaT Pharma successfully completes Global Offering of €9.1 million, strengthening financial position and supporting development of Microbiome Therapies for cancer patients Financial Position Global Offering MaaT Pharma Cancer Patients Microbiome Therapies
PRESS RELEASE published on 11/14/2025 at 23:05, 6 months 9 days ago Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...) MaaT Pharma annonce le succès de son Offre Globale de 9,1 millions d'euros pour le développement de Microbiome Ecosystem Therapies™. Levée de fonds pour Xervyteg® et MaaT033 Microbiome Ecosystem Therapies Offre Globale MaaT Pharma MaaT033 Xervyteg
BRIEF published on 11/13/2025 at 19:45, 6 months 10 days ago Lancement d'une augmentation de capital par MaaT Pharma Augmentation De Capital Investisseurs Qualifiés Offre Globale MaaT Pharma Xervyteg® Commercialisation
BRIEF published on 11/13/2025 at 19:45, 6 months 10 days ago MaaT Pharma launches a capital increase Capital Increase Qualified Investors MaaT Pharma Global Offer Xervyteg® Marketing
PRESS RELEASE published on 11/13/2025 at 19:40, 6 months 10 days ago Inside Information / Other news releases MaaT Pharma launches a capital increase of approximately €9 million through a private placement and PrimaryBid offering. Funds raised to support Xervyteg® commercialization and extend cash runway until summer 2026 Private Placement Investment Capital Increase MaaT Pharma Xervyteg
PRESS RELEASE published on 11/13/2025 at 19:40, 6 months 10 days ago Informations privilégiées / Autres communiqués MaaT Pharma lance une augmentation de capital de 9 millions d'euros pour financer son développement. Offre d'actions nouvelles aux investisseurs. Projets de développement clinique et commercialisation Développement Augmentation De Capital Commercialisation Actions Nouvelles MaaT Pharma
Published on 05/23/2026 at 19:45, 8 hours 13 minutes ago Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 1 day ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 1 day ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 1 day 1 hour ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 1 day 1 hour ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/23/2026 at 16:30, 11 hours 28 minutes ago HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 12 hours 1 minute ago EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 1 day 5 hours ago Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 1 day 5 hours ago Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 1 day 8 hours ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 19:35, 1 day 8 hours ago PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 1 day 9 hours ago Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 1 day 9 hours ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 15 hours ago Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 1 day 15 hours ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
